A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer
- Authors
- Park, Young Min; Keum, Ki Chang; Kim, Hye Ryun; Cho, Byoung Chul; Kim, Da Hee; Cho, Nam Hoon; Kim, Se-Heon
- Issue Date
- Apr-2018
- Publisher
- SPRINGER
- Citation
- ANNALS OF SURGICAL ONCOLOGY, v.25, no.4, pp 864 - 871
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- ANNALS OF SURGICAL ONCOLOGY
- Volume
- 25
- Number
- 4
- Start Page
- 864
- End Page
- 871
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/34112
- DOI
- 10.1245/s10434-017-6208-5
- ISSN
- 1068-9265
1534-4681
- Abstract
- We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3-T4 laryngo-hypopharyngeal cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Otorhinolaryngology-Head and Neck Surgery > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.